Published in Br J Haematol on May 01, 1984
Classification of exon 18 linked variants of VWF gene in von Willebrand disease. Int J Mol Epidemiol Genet (2012) 0.79
Assessment of the olfactory function in Italian patients with type 3 von Willebrand disease caused by a homozygous 253 Kb deletion involving VWF and TMEM16B/ANO2. PLoS One (2015) 0.76
Successful aortic aneurysm repair in a woman with severe von Willebrand (type 3) disease. Case Rep Hematol (2015) 0.75
Clinical utility gene card for: von Willebrand disease. Eur J Hum Genet (2011) 0.75
Outbreak of hepatitis A among Italian patients with haemophilia. Lancet (1992) 5.64
Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor. J Thromb Haemost (2006) 4.58
Availability of cadaveric kidneys for transplantation. Br Med J (1971) 4.41
Cost-benefit analysis of long-term haemodialysis for chronic renal failure. Br Med J (1975) 3.87
Gene deletions correlate with the development of alloantibodies in von Willebrand disease. J Clin Invest (1987) 3.73
Mortality from ischaemic heart disease--inter-town variation and its association with climate in England and Wales. Int J Epidemiol (1976) 3.57
Randomised controlled trial of antibiotics in patients with cough and purulent sputum. Br Med J (1976) 3.57
Transmission of non-A, non-B hepatitis by heat-treated factor VIII concentrate. Lancet (1985) 3.53
Psychological rehabilitation after myocardial infarction: multicentre randomised controlled trial. BMJ (1996) 3.05
Shortening waiting lists in orthopaedic surgery outpatient clinics. Br Med J (Clin Res Ed) (1982) 2.87
Eliminating parvovirus B19 from blood products. Lancet (1994) 2.85
Molecular pathology of haemophilia B. EMBO J (1989) 2.74
Uncertain times for research on hemophilia and allied disorders. J Thromb Haemost (2005) 2.74
Effects of exposure to air pollution on blood coagulation. J Thromb Haemost (2006) 2.52
A cytoplasmic dynein heavy chain is required for oscillatory nuclear movement of meiotic prophase and efficient meiotic recombination in fission yeast. J Cell Biol (1999) 2.48
Accuracy of cancer registration. Br J Prev Soc Med (1976) 2.44
Factor 8 on the vascular intima: possible importance in haemostasis and thrombosis. Nat New Biol (1973) 2.43
The spindle pole body of Schizosaccharomyces pombe enters and leaves the nuclear envelope as the cell cycle proceeds. Mol Biol Cell (1997) 2.41
High risk of cerebral-vein thrombosis in carriers of a prothrombin-gene mutation and in users of oral contraceptives. N Engl J Med (1998) 2.30
Increased factor IX levels in puerperium during administration of diethylstilboestrol. Br Med J (1968) 2.29
Oligospecificity of the cellular adhesion receptor Mac-1 encompasses an inducible recognition specificity for fibrinogen. J Cell Biol (1988) 2.28
Long-term evaluation of HIV antigen and antibodies to p24 and gp41 in patients with hemophilia. Potential clinical importance. N Engl J Med (1987) 2.18
Effects on bleeding complications of pharmacogenetic testing for initial dosing of vitamin K antagonists: a systematic review and meta-analysis. J Thromb Haemost (2014) 2.15
Patients with type 3 severe von Willebrand disease are not protected against atherosclerosis: results from a multicenter study in 47 patients. Circulation (2004) 2.12
Heightened interaction between platelets and factor VIII/von Willebrand factor in a new subtype of von Willebrand's disease. N Engl J Med (1980) 2.07
Regional variations in need for and provision and use of child health services in England and Wales. Br Med J (1976) 2.06
1-Deamino-8-d-arginine vasopressin: a new pharmacological approach to the management of haemophilia and von Willebrands' diseases. Lancet (1977) 2.06
Human recombinant DNA-derived antihemophilic factor (factor VIII) in the treatment of hemophilia A. recombinant Factor VIII Study Group. N Engl J Med (1990) 2.05
Inherited thrombophilia: pathogenesis, clinical syndromes, and management. Blood (1996) 2.02
Expression studies on a novel type 2B variant of the von Willebrand factor gene (R1308L) characterized by defective collagen binding. J Thromb Haemost (2005) 2.02
Inherited thrombophilia: Part 1. Thromb Haemost (1996) 2.00
The risk of recurrent deep venous thrombosis among heterozygous carriers of both factor V Leiden and the G20210A prothrombin mutation. N Engl J Med (1999) 1.97
Clinical judgment in the diagnosis and management of frequency and dysuria in general practice. Br Med J (Clin Res Ed) (1984) 1.93
Thromboembolic disease--critical evaluation of laboratory investigation. Thromb Haemost (1992) 1.93
Fibrinolytic activity of human veins. Lancet (1967) 1.91
Factor VIIa and antithrombin III activity during severe sepsis and septic shock in neutropenic patients. Blood (1996) 1.88
Factor V gene mutation is a risk factor for cerebral venous thrombosis. Thromb Haemost (1996) 1.83
Prothrombotic genetic risk factors in young survivors of myocardial infarction. Blood (1999) 1.81
Interaction between fibrinogen and cultured endothelial cells. Induction of migration and specific binding. J Clin Invest (1985) 1.79
AHF related protein in clinical praxis. Scand J Haematol (1974) 1.78
A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study). J Thromb Haemost (2011) 1.75
Defective fibrinolysis in blood and vein walls in recurrent "idiopathic" venous thrombosis. Acta Chir Scand (1972) 1.74
Carrier detection by direct gene analysis in a family with haemophilia B (factor IX deficiency). Lancet (1984) 1.74
Contribution of Gardnerella vaginalis to vaginitis in a general practice. Br Med J (Clin Res Ed) (1986) 1.72
Treatment of severe von Willebrand disease with a high-purity von Willebrand factor concentrate (Wilfactin): a prospective study of 50 patients. J Thromb Haemost (2007) 1.69
Genetic screening for hemophilia A (classic hemophilia) with a polymorphic DNA probe. N Engl J Med (1985) 1.67
Platelet membrane glycoproteins implicated in ristocetin-induced aggregation. Studies of the proteins on platelets from patients with Bernard-Soulier syndrome and von Willebrand's disease. J Clin Invest (1976) 1.67
The incidence and distribution of CpG----TpG transitions in the coagulation factor IX gene. A fresh look at CpG mutational hotspots. Nucleic Acids Res (1990) 1.64
Clinical pharmacology of aminocaproic and tranexamic acids. J Clin Pathol Suppl (R Coll Pathol) (1980) 1.64
Rate of inhibitor development in previously untreated hemophilia A patients treated with plasma-derived or recombinant factor VIII concentrates: a systematic review. J Thromb Haemost (2010) 1.62
Impact, diagnosis and treatment of von Willebrand disease. Thromb Haemost (2000) 1.62
Intra-articularly localized bacterial DNA containing CpG motifs induces arthritis. Nat Med (1999) 1.61
Effect on blood coagulation of massive intravascular haemolysis. Blood (1969) 1.61
Absence of antibodies to AIDS virus in haemophiliacs treated with heat-treated Factor VIII concentrate. Lancet (1985) 1.60
A radiologic classification of hemophilic arthropathy. Clin Orthop Relat Res (1980) 1.59
A 23bp insertion in the endothelial protein C receptor (EPCR) gene impairs EPCR function. Thromb Haemost (2001) 1.57
Different bleeding risk in type 2A and 2M von Willebrand disease: a 2-year prospective study in 107 patients. J Thromb Haemost (2012) 1.57
Median sternotomy wound dehiscence: a retrospective case control study of risk factors and outcome. J R Coll Surg Edinb (1992) 1.56
High death rates: more deaths or earlier deaths? J R Coll Physicians Lond (1987) 1.56
Purinoceptors on blood platelets: further pharmacological and clinical evidence to suggest the presence of two ADP receptors. Br J Haematol (1995) 1.55
A multicenter pharmacokinetic study of the B-domain deleted recombinant factor VIII concentrate using different assays and standards. J Thromb Haemost (2003) 1.53
Hepatitis C virus transmission by monoclonal antibody purified factor VIII concentrate. Lancet (1990) 1.53
Intrauterine death and circulating anticoagulant ("antithromboplastin"). Acta Med Scand (1975) 1.51
A nascent secretory protein may traverse the ribosome/endoplasmic reticulum translocase complex as an extended chain. J Biol Chem (1996) 1.51
pkl1(+)and klp2(+): Two kinesins of the Kar3 subfamily in fission yeast perform different functions in both mitosis and meiosis. Mol Biol Cell (2001) 1.50
Type and location of venous thromboembolism in patients with factor V Leiden or prothrombin G20210A and in those with no thrombophilia. J Thromb Haemost (2006) 1.48
Reduction in transmission of hepatitis C after the introduction of a heat-treatment step in the production of C1-inhibitor concentrate. Transfusion (1995) 1.48
Determination of plasminogen in clots and thrombi. Thromb Diath Haemorrh (1966) 1.48
Coagulation and fibrinolytic studies during pregnancy. Acta Obstet Gynecol Scand (1967) 1.48
Different risks of thrombosis in four coagulation defects associated with inherited thrombophilia: a study of 150 families. Blood (1998) 1.47
Mechanism of plasminogen activator and factor VIII increase after vasoactive drugs. Br J Haematol (1975) 1.47
Factors affecting adherence to guidelines for antithrombotic therapy in elderly patients with atrial fibrillation admitted to internal medicine wards. Eur J Intern Med (2010) 1.47
Clinical decision-making: coping with uncertainty. Postgrad Med J (2002) 1.47
Geographical variation mortality from ischaemic heart disease in England and Wales. Br J Prev Soc Med (1977) 1.46
Haemophilia prophylaxis in Sweden. Acta Paediatr Scand (1976) 1.46
Rare coagulation disorders. Thromb Haemost (1999) 1.46
Status of present and candidate international reference preparations (IRP) of thromboplastin for the prothrombin time. A report of the Subcommittee for Control of Anticoagulation. Thromb Haemost (1993) 1.45
Variations in gastric cancer mortality in South Wales. Clin Oncol (1979) 1.45
Risk factors for deep venous thrombosis of the upper extremities. Ann Intern Med (1997) 1.45
Haemophilia prophylaxis in young patients--a long-term follow-up. J Intern Med (1997) 1.44
Intravascular coagulation and acute renal failure in a child with mycoplasma infection. Acta Med Scand (1971) 1.44
Multicentric evaluation of a new PT reagent based on recombinant human tissue factor and synthetic phospholipids. Thromb Haemost (1994) 1.43
A simplified procedure for thromboplastin calibration--the usefulness of lyophilized plasmas assessed in a collaborative study. Thromb Haemost (1996) 1.43
Loss of skeletal calcium by patients on maintenance dialysis. Br Med J (1970) 1.42
Arg506Gln factor V mutation and cerebral ischemia in the young. Stroke (1996) 1.42
A comparison of subjective responses in a trial comparing endocrine with cytotoxic treatment in advanced carcinoma of the breast. Eur J Cancer (1980) 1.42
A mathematical model of an integrated haemodialysis and renal transplantation programme. Br J Prev Soc Med (1974) 1.41
Hemophilia and nonprogressing human immunodeficiency virus type 1 infection. Blood (1997) 1.41
Provision, uptake and cost of cardiac rehabilitation programmes: improving services to under-represented groups. Health Technol Assess (2004) 1.41
Multimeric pattern of plasma and platelet von Willebrand factor is normal in uremic patients. Am J Hematol (1993) 1.40
Factor VII clotting assay: influence of different thromboplastins and factor VII-deficient plasmas. CISMEL Study Group. Thromb Haemost (1991) 1.40
Resistance to activated protein C mimicking dysfunctional protein C: diagnostic approach. Blood Coagul Fibrinolysis (1996) 1.39
Frequency of factor V Arg506 Gln in Italians. Thromb Haemost (1996) 1.39
[Threatened future of plasma products. Who is responsible?]. Lakartidningen (1996) 1.39
Poor comparability of prothrombin fragment 1 + 2 values measured by two commercial ELISA methods: influence of different anticoagulants and standards. Thromb Haemost (1994) 1.38
Calibration of local systems with lyophilized calibrant plasmas improves the interlaboratory variability of the INR in the Italian external quality assessment scheme. Thromb Haemost (1999) 1.38